Protein Chromatography Impurity Clearance Patents: Leaders & White Space 2026
- 28.7% of all 651 records sit with just five assignees, yet the ranked field runs 100 companies deep — concentration at the top, a long tail below it.
- Filing peaked in 2017 at 39 and 2021-to-2024 activity fell 29%, though 2025-26 counts are still filling in given an ~18-month publication lag.
- C07K dominates at 90.8% of records while B01J catalysis-linked filings sit at just 13.1% — a narrower, less-claimed branch worth checking before drafting.
Filing growth compares 2021 (7 records) with 2024 (5) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 651 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Protein chromatography impurity clearance covers the methods and reagents used to strip host-cell protein, residual DNA, aggregates and leached ligand out of a biologic during downstream purification. The scope here centres on protein A and affinity chromatography combined with purity-assessment claims, filtered to B01D15/08, C07K1/16 and C12N9/00 — the classes covering separation hardware, protein/peptide purification and enzyme-based processing respectively. Records span 2015 through the 2026 data cut-off, with the most recent year necessarily undercounted because publication trails filing by roughly 18 months.
651 records and as many families sit in scope, ranked across 100 assignees. That breadth means the field is neither a single-company moat nor fully open: a handful of filers account for a meaningful share of the total, but most of the ranked list holds only a handful of filings each.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 651 records: how filing activity has moved year over year, and which IPC subclasses carry the claim density.
Filing trend: a 2017 peak, then a slower decade
Filings hit their peak in 2017 at 39 records. From 2021 (7) to 2024 (5) — the last year treatable as complete — activity fell 29%. Years after 2024 are still filling in under the publication lag and should not be read as a continued decline.
Technology composition: peptide purification dominates
C07K (peptides & proteins) touches 90.8% of the 651 records, with C12N (microorganisms & genetic engineering) at 45.0%. Separation hardware under B01D sits at 28.7%, and catalysis-linked B01J claims cover only 13.1% — since a record can carry several classes, these shares add to more than 100% and should not be summed.
Shares are the percentage of the 651 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Protein Chromatography Impurity Clearance with Eureka
This page is one run against one query. Ask Eureka your own question about protein chromatography impurity clearance and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited and most representative filings
WO2020125757A1 — A method for improving aggregate removal by protein A chromatography
Protein A chromatography is generally less effective in removing antibody aggregates under typical conditions. The filing describes a combination of polyethylene glycol (PEG) and a salt (chaotropic or kosmotropic) used as wash and elution buffer additives. Their synergistic effect achieves near-complete separation of monomer from aggregates; in the demonstration case aggregates in the elution pool fell from 20% to 3-4% compared with the control run.Filed by WUXI BIOLOGICS (SHANGHAI) CO., LTD., published 2020-06-25.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO1993023569A1 | Method and reagent for inhibiting viral replication | 982 |
| 2 | US20090187005A1 | Enhanced purification of antibodies and antibody fragments by apatite chromatography | 282 |
| 3 | US6479258B1 | Non-stochastic generation of genetic vaccines | 170 |
| 4 | US6713279B1 | Non-stochastic generation of genetic vaccines and enzymes | 124 |
| 5 | EP2682168A1 | Purification of biological molecules | 117 |
| 6 | US20140255994A1 | Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances | 110 |
| 7 | US20030207287A1 | Non-stochastic generation of genetic vaccines | 109 |
| 8 | WO2000046344A2 | Non-stochastic generation of genetic vaccines and enzymes | 96 |
| 9 | US20090130718A1 | Gene site saturation mutagenesis | 95 |
| 10 | US7618799B2 | Bacterial leader sequences for increased expression | 92 |
Citation counts favour older records simply by virtue of longer exposure — read them as a signal of influence within this corpus, not of current technical importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for a filing decision
Three read-outs from the composition and concentration figures above, translated into what they imply for someone drafting or clearing claims in this space.
The top of the field is dense, the rest is thin
Five assignees hold 28.7% of all 651 records and the ranked leaders extend the count to 44.9% at ten. Below that the ranking runs another 90 companies, each typically holding only a handful of filings — a pattern of a concentrated core surrounded by single- or few-filing entrants.
Activity has cooled from its 2017 peak
The peak year on record is 2017 at 39 filings. The 2021-to-2024 window, the last stretch that can be read as complete, shows a 29% drop. That is a real signal about recent drafting pace, not a sign the underlying problem is solved — impurity clearance claims keep surfacing, just at a slower rate.
Catalysis-adjacent claims are the thinnest major branch
C07K claims cover 90.8% of records and C12N 45.0%, so peptide-purification and genetic-engineering claim space is heavily occupied. B01J, covering chemical and physical processes including catalysis, sits at only 13.1% — a narrower footprint relative to the rest of the composition.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to protein chromatography impurity clearance, with the prior art for and against each one.
The assignee landscape
100 companies make up the full ranked list returned for this search — not a top-50 or top-100 cut, but the entire ranking the dataset produces. A leader with 67 records sits well ahead of fifth place at 26 and tenth at 19, illustrating the same concentrated-top, long-tail pattern seen in the overall share figures.
One assignee leads by a wide margin
The top-ranked assignee holds 67 records, more than double the fifth-place count of 26 — a gap that marks out a genuine leader rather than a tie at the top.
The drop-off from fifth to tenth is gradual
Between fifth place (26 records) and tenth (19), the decline is steady rather than steep, suggesting a genuine second tier of active filers rather than a cliff straight into single-digit players.
Momentum has slowed even among top filers
Recent-year momentum data shows most of the historically active assignees filing zero records in the latest year, with only a single filer adding one. That is consistent with the broader 2021-to-2024 decline rather than a sign any one leader has pulled ahead recently.
| Assignee | Recent year | YoY |
|---|---|---|
| MedImmune LLC | 1 | — |
| Agency for Science, Technology and Research (A*STAR) | 0 | — |
| EMD Millipore Corp | 0 | — |
| Bio-Rad Laboratories, Inc. | 0 | -100% |
| Coherus Oncology Inc | 0 | — |
| Genzyme Corp | 0 | — |
| The Scripps Research Institute | 0 | — |
| The Trustees of Princeton University | 0 | — |
Where to take this analysis
The figures above set the boundaries of the field. Turning them into a filing or clearance decision means going deeper on specific claims and assignees.
Map claims against the leader's portfolio
Start with the top-ranked assignee's 67 records before assessing the rest of the ranked field, since its scope is the most likely source of blocking claims.
Explore assignee portfolios in EurekaCheck the under-claimed branches directly
B01J-linked catalysis claims and other thinner branches identified above are worth a targeted search before drafting new claims in those areas.
Run a white-space search in EurekaTrack filings past the publication lag
2025-26 counts will keep rising as filings publish; re-check the trend in a few quarters rather than treating the current dip as final.
Set up filing alerts in EurekaCommon questions on this landscape
The ranked list covers 100 companies, with one clear leader holding 67 records — more than double the fifth-place count of 26. The top five assignees combined account for 28.7% of all 651 records in scope, and the top ten for 44.9%. Below the leading group the ranking thins into a long tail of companies with only a handful of filings each, so a full freedom-to-operate check needs to look well past the leader alone.
Filing peaked in 2017 at 39 records and has cooled since; the 2021-to-2024 window, the most recent stretch that can be treated as complete, shows a 29% decline from 7 to 5 filings. Counts for 2025 and 2026 are still low, but that reflects the roughly 18-month lag between filing and publication rather than an actual drop in activity. The honest read is a slowdown through 2024, with the true 2025-26 picture not yet visible.
C07K (peptides and proteins) is the dominant class, appearing in 90.8% of the 651 records in scope, followed by C12N (microorganisms and genetic engineering) at 45.0%. Separation-process claims under B01D appear in 28.7% of records, and catalysis-related B01J claims in only 13.1%. Because a single record can carry several IPC classes, these shares add up to more than 100% and should not be summed into a single total.
WO2020125757A1, filed by WUXI BIOLOGICS, claims a method for improving aggregate removal during protein A chromatography using a combination of polyethylene glycol and a salt as wash and elution buffer additives. The demonstrated result reduced aggregates in the elution pool from 20% to 3-4% compared with an unmodified control. Anyone working on aggregate removal at the capture step should review this filing's claim scope before designing a similar buffer additive approach.
The IPC composition points to catalysis-linked claims under B01J, covering only 13.1% of the 651 records, as one of the thinner branches relative to the heavily claimed C07K and C12N space. Specific sub-areas worth checking include catalysis-assisted impurity elution, enzymatic host-cell protein digestion assays, and leached ligand quantification methods. A thinner IPC share is a starting signal, not a guarantee of open claim space, so it still warrants a targeted prior-art search before drafting.
Research Protein Chromatography Impurity Clearance in depth with Eureka
Go past this page: query the whole protein chromatography impurity clearance corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.